Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir/ritonavir: a retrospective observational study

• Egile Nagusiak: Takeshi Tomida (Egilea), Takeshi Kimura (Egilea), Kazuhiro Yamamoto (Egilea), Atsushi Uda (Egilea), Yuki Matsumoto (Egilea), Naoki Tamura (Egilea), Masashi Iida (Egilea), Akiko Tanifuji (Egilea), Kumiko Matsumoto (Egilea), Naomi Mizuta (Egilea), Kei Ebisawa (Egilea), Goh Ohji (Egilea), Tomohiro Omura (Egilea), Kentaro Iwata (Egilea), Ikuko Yano (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2024-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Purpose While nirmatrelvir/ritonavir (NMV-r) has been positioned as a first-line treatment for mild to moderate COVID-19, it has multiple and significant drug-drug interactions (DDIs). The use of NMV-r in Japan has been limited compared to the United States. This study aimed to describe the...